The American Society of Clinical Oncology (ASCO) commends Congress for passing a continuing resolution that includes an important correction to the Merit-based Incentive Payment System. We are also pleased to see a budget deal that commits to at least a $2 billion funding increase for the National Institutes of Health (NIH) to reclaim America’s leadership in cancer research and continue building on our tremendous progress towards understanding, preventing, and treating cancer.
The American Society of Clinical Oncology (ASCO) today released its review of leading oncology pathway vendors in the United States. "Oncology Clinical Pathways: Charting the Landscape of Pathway Providers," published in the Journal of Oncology Practice (JOP), examines the clinical pathways offered by six commercial vendors using the society's criteria for high-quality clinical pathways.
ALEXANDRIA, Va. – In a phase III clinical trial of people with previously untreated metastatic renal cell cancer (mRCC), combining immunotherapy atezolizumab with targeted therapy bevacizumab delayed cancer growth by about three months longer than sunitinib, another targeted therapy. The benefit of atezolizumab plus bevacizumab was greater for patients with PD-L1-positive tumors. These findings will be presented at the upcoming 2018 Genitourinary Cancers Symposium in San Francisco, California.
ALEXANDRIA, Va. – Findings from the phase III placebo-controlled SPARTAN trial suggest that apalutamide is an effective treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk for developing metastatic disease, and for whom no approved treatments exist. Men who received apalutamide had a 72% lower risk of metastasis or death than those who received placebo.
Researchers have developed a model to predict overall survival for people with advanced urothelial cancers treated with the immune checkpoint inhibitor atezolizumab. The model, which is based on six clinical factors, may help inform treatment decisions for use of atezolizumab in these patients. These findings will be presented at the upcoming 2018 Genitourinary Cancers Symposium in San Francisco, California.
ALEXANDRIA, Va. – A new analysis of the ongoing STAMPEDE clinical trial found that adding the chemotherapy drug docetaxel to hormone therapy for advanced prostate cancer improves quality of life and lowers the need for subsequent therapy. Docetaxel was also found to be cost-effective. These findings will be presented at the upcoming 2018 Genitourinary Cancers Symposium in San Francisco, California.
"Over the past few decades we’ve seen global cancer death rates drop thanks to dramatic improvements in diagnosis and treatment. But the unfortunate reality is that millions of patients worldwide are not yet reaping the benefits of the progress we’ve made because of inability to access care. All too often, where someone lives dictates their chances of surviving cancer."
Co-sponsors of the 2018 Cancer Survivorship Symposium announced today five abstracts that will be highlighted in the meeting’s official Press Program. Researchers will present the findings of these studies in an embargoed presscast for reporters, taking place Monday, February 12, 2018, from 12:00 noon – 1:30 p.m. ET.
The American Society of Clinical Oncology (ASCO) congratulates Alex Azar for his confirmation as Secretary of the U.S. Department of Health and Human Services (HHS). As the head of HHS, Secretary Azar has an opportunity to help address critical issues facing the cancer care delivery system, including increasing access to high-quality care, addressing the high cost of care, and supporting the development and dissemination of innovative treatments
ALEXANDRIA, Va. — CancerLinQ LLC and the American College of Medical Genetics and Genomics (ACMG), the medical specialty society for clinical and laboratory genetics professionals, have entered into a programmatic collaboration. CancerLinQ®, the American Society of Clinical Oncology’s (ASCO) health information technology platform designed by oncologists for oncologists to leverage the power of big data to help improve the quality of care for patients with cancer, will benefit from the knowledge and expertise of ACMG leadership and members.
SAN FRANCISCO – Eight noteworthy studies exploring the implications of immuno-oncology for patient care will be presented at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium. The meeting will take place January 25-27 at the San Francisco Marriott Marquis in San Francisco, California. These notable abstracts discuss the efficacy of immunotherapy in rare cancers, biomarkers to predict which patients will benefit most, and managing the adverse effects of immune-based treatments.
ALEXANDRIA, Va. — A registry that tracks the quality of medical care provided to patients receiving cancer treatment launched this month as part of a collaboration between the American Society of Clinical Oncology (ASCO) and the American Society for Radiation Oncology (ASTRO). In addition to improving the quality of care for people living with cancer, the Quality Oncology Practice Initiative (QOPI®) Reporting Registry also makes it easier for medical and radiation oncologists to report quality-related performance metrics required by the federal government.
ALEXANDRIA, Va. – A new study has found that a test that identifies circulating tumor cells (CTCs) present in the bloodstream can detect colorectal cancer at an early stage, with accuracy ranging from 84 to 88%. Most prior studies using CTCs have been able to detect late-stage colorectal cancer, and this study is one of the first clinical studies to show that CTCs can be useful for detecting early, more treatable stages of the cancer. These findings will be presented at the upcoming 2018 ASCO Gastrointestinal Cancers Symposium in San Francisco, California.
ALEXANDRIA, Va. – Co-sponsors of the 2018 Genitourinary Cancers Symposium announced today four abstracts to be highlighted in the meeting’s official Press Program. Researchers will present the findings of these studies in an embargoed presscast for reporters, taking place Monday, February 5, 2018, from 12:00 noon – 1:30 p.m. ET.